Enterprise value of Exelixis, Inc.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
|AY Atlantica Yield plc||NASDAQ||$7.8469B|
|HHC Howard Hughes Corporation (The)||NYSE > Consumer Services > Real Estate Investment Trusts||$7.857B|
|WBS Webster Financial Corporation||NYSE > Finance > Major Banks||$7.8573B|
|JEC Jacobs Engineering Group Inc.||NYSE > Basic Industries > Military/Government/Technical||$7.8905B|
|TER Teradyne, Inc.||NYSE > Capital Goods > Electrical Products||$7.8984B|
|TDY Teledyne Technologies Incorporated||NYSE > Capital Goods > Industrial Machinery/Components||$7.9145B|
|EXEL Exelixis, Inc.||NASDAQ > Health Care > Biotechnology: Commercial Physical & Biological Resarch||$7.9168B|
|HDB HDFC Bank Limited||NYSE > Finance > Commercial Banks||$561.12B|
|AMZN Amazon.com, Inc.||NASDAQ > Consumer Services > Catalog/Specialty Distribution||$642.7B|
|MSFT Microsoft Corporation||NASDAQ > Technology > Computer Software: Prepackaged Software||$650.73B|
|GOOG Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$690.32B|
|GOOGL Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$695.27B|
|AAPL Apple Inc.||NASDAQ > Technology > Computer Manufacturing||$957.55B|